文献速递临床试验与 GCP新药、器械与细胞基因治疗研发基础与转化研究

每周一次艾塞那肽与安慰剂治疗帕金森病的随机双盲安慰剂对照试验

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Lancet · 2017-08-03

这项单中心随机双盲安慰剂对照试验将62例中度帕金森病患者按1:1分配,分别接受每周一次皮下注射艾塞那肽2 mg或安慰剂48周,随后洗脱12周。第60周停药状态下MDS-UPDRS第3部分评分艾塞那肽组改善1.0分、安慰剂组恶化2.1分,校正后平均差异为-3.5分(95%CI -6.7至-0.3;p=0.0318)。两组注射部位反应和胃肠道症状常见,严重不良事件分别为6例和2例,均判定与研究干预无关。

要点

  • 第60周停药状态下MDS-UPDRS第3部分评分艾塞那肽组改善1.0分,安慰剂组恶化2.1分,校正后平均差异-3.5分(95%CI -6.7至-0.3;p=0.0318)。
  • 艾塞那肽组发生6例严重不良事件,安慰剂组2例,均判定与研究干预无关。
  • 艾塞那肽对停药状态运动评分有正面影响且持续至暴露期后。

核心结论

  • 艾塞那肽对帕金森病实际定义的停药状态运动评分有正面影响,且持续至暴露期后。
  • 艾塞那肽是否影响 underlying disease pathophysiology 或仅产生持久对症效应尚不确定。
  • 艾塞那肽代表帕金森病研究的重要新方向,其对日常症状的影响需在更长程试验中考察。

研究设计与样本

  • 单中心、随机、双盲、安慰剂对照试验。
  • 纳入年龄25-75岁、符合Queen Square Brain Bank标准的特发性帕金森病患者,正在接受多巴胺能药物治疗且存在剂末现象,治疗状态下Hoehn和Yahr分期≤2.5期。
  • 患者按1:1随机分配接受每周一次皮下注射艾塞那肽2 mg或安慰剂,共48周,加常规用药,随后洗脱12周。
  • 随机化采用基于网络的随机化,按疾病严重程度进行两层区组设计。
  • 主要结局为第60周实际定义的停药状态下运动障碍学会统一帕金森病评定量表(MDS-UPDRS)运动亚量表(第3部分)的校正差异。

主要发现

  • 2014年6月18日至2015年3月13日共入组并随机分配62例患者,艾塞那肽组32例,安慰剂组30例。
  • 主要分析纳入艾塞那肽组31例和安慰剂组29例。
  • 第60周停药状态下MDS-UPDRS第3部分评分艾塞那肽组改善1.0分(95%CI -2.6至0.7),安慰剂组恶化2.1分(95%CI -0.6至4.8),校正后平均差异为-3.5分(95%CI -6.7至-0.3;p=0.0318)。
  • 两组注射部位反应和胃肠道症状均为常见不良事件。
  • 艾塞那肽组发生6例严重不良事件,安慰剂组2例,两组均无严重不良事件被判定与研究干预相关。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 艾塞那肽是否影响 underlying disease pathophysiology 或仅产生持久对症效应尚不确定。
  • 原文结论指出需在更长程试验中考察艾塞那肽对日常症状的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has neuroprotective effects in preclinical models of Parkinson's disease. We investigated whether these effects would be apparent in a clinical trial. METHODS: In this single-centre, randomised, double-blind, placebo-controlled trial, patients with moderate Parkinson's disease were randomly assigned (1:1) to receive subcutaneous injections of exenatide 2 mg or placebo once weekly for 48 weeks in addition to their regular medication, followed by a 12-week washout period. Eligible patients were aged 25-75 years, had idiopathic Parkinson's disease as measured by Queen Square Brain Bank criteria, were on dopaminergic treatment with wearing-off effects, and were at Hoehn and Yahr stage 2·5 or less when on treatment. Randomisation was by web-based randomisation with a two strata block design according to disease severity. Patients and investigators were masked to treatment allocation. The primary outcome was the adjusted difference in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor subscale (part 3) in the practically defined off-medication state at 60 weeks. All efficacy analyses were based on a modified intention-to-treat principle, which included all patients who completed any post-randomisation follow-up assessments. The study is registered at ClinicalTrials.gov (NCT01971242) and is completed. FINDINGS: Between June 18, 2014, and March 13, 2015, 62 patients were enrolled and randomly assigned, 32 to exenatide and 30 to placebo. Our primary analysis included 31 patients in the exenatide group and 29 patients in the placebo group. At 60 weeks, off-medication scores on part 3 of the MDS-UPDRS had improved by 1·0 points (95% CI -2·6 to 0·7) in the exenatide group and worsened by 2·1 points (-0·6 to 4·8) in the placebo group, an adjusted mean difference of -3·5 points (-6·7 to -0·3; p=0·0318). Injection site reactions and gastrointestinal symptoms were common adverse events in both groups. Six serious adverse events occurred in the exenatide group and two in the placebo group, although none in either group were judged to be related to the study interventions. INTERPRETATION: Exenatide had positive effects on practically defined off-medication motor scores in Parkinson's disease, which were sustained beyond the period of exposure. Whether exenatide affects the underlying disease pathophysiology or simply induces long-lasting symptomatic effects is uncertain. Exenatide represents a major new avenue for investigation in Parkinson's disease, and effects on everyday symptoms should be examined in longer-term trials. FUNDING: Michael J Fox Foundation for Parkinson's Research.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017. PMID: 28781108. doi:10.1016/S0140-6736(17)31585-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。